Real-time · AI · Cross-signal
Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on BetterLife Pharma — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
BetterLife Announces Closing of a Private Placement for BETR-001 and BETR-002 Compounds
Jul 02, 2024•almost 2 years ago
Contract Type
partnership
VancouverBiotechnologyDescription
BetterLife Pharma Inc. announced the closing of a non-brokered private placement, pursuant to which the Company issued 1,750,000 units at a price of $0.10 per Unit for aggregate gross proceeds of $175,000. The company primarily focuses on developing and commercializing BETR-001 and BETR-002 compounds to treat neuro-psychiatric and neurological disorders.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months